AGP Picks
View all

Alternative Medicine Times
Provided by AGP

Alternative Medicine Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alternative Medicine Times.

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on October 12, 2026

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
Oct. 12, 2026

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Indeterminate GlobeNewswire
Beacon Therapeutics Presents Data from Pivotal VISTA Trial of Laru-zova at AAO 2026
Oct. 12, 2026

Beacon Therapeutics Presents Data from Pivotal VISTA Trial of Laru-zova at AAO 2026

Indeterminate GlobeNewswire
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
Oct. 12, 2026

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

Indeterminate GlobeNewswire
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
Oct. 12, 2026

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

Indeterminate GlobeNewswire
Vivani Medical Announces Participation in Upcoming Investor Conferences
Oct. 12, 2026

Vivani Medical Announces Participation in Upcoming Investor Conferences

Indeterminate GlobeNewswire
ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting
Oct. 12, 2026

ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting

Indeterminate GlobeNewswire
Gates Foundation and Wellcome Leap Commit $100 Million to Reduce Global Stillbirth Rates
Oct. 12, 2026

Gates Foundation and Wellcome Leap Commit $100 Million to Reduce Global Stillbirth Rates

Indeterminate GlobeNewswire
MediciNova CEO Provides Shareholder Update
Oct. 12, 2026

MediciNova CEO Provides Shareholder Update

Indeterminate GlobeNewswire
LULU Investigation News: The Lululemon Securities Fraud Investigation into 17% Stock Drop is Pending – Investors Notified to Contact BFA Law
Oct. 12, 2026

LULU Investigation News: The Lululemon Securities Fraud Investigation into 17% Stock Drop is Pending – Investors Notified to Contact BFA Law

Indeterminate GlobeNewswire
Concept Life Sciences Appoints Dr Adrijana Vinter as Chief Executive Officer
Oct. 12, 2026

Concept Life Sciences Appoints Dr Adrijana Vinter as Chief Executive Officer

Indeterminate GlobeNewswire
Elite women cyclists gear up for three-stage Tour of Chongming Island
Oct. 12, 2026

Elite women cyclists gear up for three-stage Tour of Chongming Island

Indeterminate GlobeNewswire
Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiometabolic disease spectrum including obesity
Oct. 12, 2026

Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiometabolic disease spectrum including obesity

Indeterminate GlobeNewswire
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
Oct. 12, 2026

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer

Indeterminate GlobeNewswire
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
Oct. 12, 2026

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

Indeterminate GlobeNewswire

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Alternative Medicine Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.